CClinicalTrials.gg
CompletedNCT03386331Updated Feb 4, 2021

VDR Gene Polymorphisms and Weight Loss in Non-diabetic Overweight and Obese Subjects

An interventional study of diet and exercise in Overweight and Obesity, sponsored by Diabetes Foundation, India. Completed at 1 site in India. Open to participants aged 20 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-04.

Sponsored by Diabetes Foundation, India · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
20 Years to 60 Years
Sex
All
01

Study summary

This is a six months intervention study in non-diabetic overweight and obese subjects. Subjects will be counseled for weight loss through diet and exercise. Diet and exercise will be recommended as per the regular norms for weight loss (weight loss ≥10% from baseline weight will be considered as a significant loss of weight) for overweight and obese subjects. A sample size of 90 subjects was calculated but assuming a drop out rate of 20%, 110 subjects will be enrolled. Enrolled subjects will be measured at every visit (monthly) for weight, body composition measures of abdominal obesity and skin folds. They would be assessed for compliance with diet and exercise. Detailed analysis of body composition including DXA, biochemical analysis will be performed at enrollment and after six months intervention. Statistical analysis will be performed to find association between measures of body composition for weight loss and genotypes of the VDR polymorphisms.

Read the detailed description

This is a six months intervention study in non-diabetic overweight and obese subjects. Subjects will be counseled for weight loss through diet and exercise. Diet and exercise will be recommended as per the regular norms for weight loss (weight loss ≥10% from baseline weight will be considered as a significant loss of weight) for overweight and obese subjects. A sample size of 90 subjects was calculated but assuming a drop out rate of 20%, 110 subjects will be enrolled. Enrolled subjects will be measured at every visit (monthly) for weight, body composition measures of abdominal obesity and skin folds. They would be assessed for compliance with diet and exercise. Detailed analysis of body composition including DXA, biochemical analysis will be performed at enrollment and after six months intervention. Statistical analysis will be performed to find association between measures of body composition for weight loss and genotypes of the VDR polymorphisms.

VDR Polymorphisms

Polymorphisms in the VDR gene have been identified through out the complete VDR gene region and associated with cancer and autoimmune diseases. The FokI polymorphism is present in the translation site and results in the VDR protein being shortened by three amino acids and is not linked with any other VDR polymorphisms. This polymorphism predisposes to bone-disease, risk of cancer, immune mediated diseases 147-149,150, 151.

The common VDR gene polymorphisms are BsmI, TaqI, ApaI and FokI. These polymorphisms have shown varying results with insulin sensitivity and secretion.

02

Conditions studied

  • Overweight
  • Obesity
03

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • 20-60 yrs
  • BMI ≥ 23 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Type 1 or Type 2 Diabetes.
  • On drugs or meal supplements for weight loss.
  • On calcium and or vitamin D supplement currently or in the previous six months.
  • Have past or current history or family history of renal stones.
  • Have participated in any other investigational drug study in the previous three months.
  • Have any systemic diseases (cardiac, hepatic, endocrine or renal) or taking any kind of treatment more than one month in the last six months.
  • Diagnosed malabsorption (celiac disease, Cohn's, ulcerative colitis) or history suggestive of malabsorption.
  • Have past history of bariatric surgery
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Other
    Diet and Exercise

    Behavioral: diet and exercise

Interventions

  • Behavioraldiet and exercise

    Diet and lifestyle intervention

05

What researchers measure

Primary outcomes

  1. Body weight (Kg)

    weight loss

    Time frame: 6 months

Secondary outcomes

  1. Genetic polymorphism

    BsmI, TaqI, ApaI, FokI

    Time frame: 6 months

06

Study locations

1 site
  • Anoop misra
    New Delhi, India
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03386331
Lead sponsor
Diabetes Foundation, India
Collaborators
Indian Council of Medical Research
Responsible party
Dr Anoop Misra (Director, Diabetes Foundation, India) — Principal investigator
First posted
Dec 29, 2017
Start date
Mar 16, 2016
Primary completion
Mar 30, 2019
Completion
Mar 30, 2019
Last update
Feb 4, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion